Install
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
- 81articles · 30d
- 1+ day agolatest article
- Aug 18, 2026earliest in window
- 94%with images
- 227avg words
- Business & Industrial 56
- Medical 46
- Economy, Business & Finance 38
- Finance & Business 23
- Health 23
- Health & Wellness 23
- Science & Technology 18
- Science & Nature 6
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
HHS Confirms Four Senior FDA Leaders, Including Agency's First-Ever AI Deputy Commissioner
4+ day, 18+ hour ago (449+ words) Pharmaceutical Executive...
What Moments in FDA???s Review Process Should Patients and Providers be Watching Closely?
1+ week, 4+ day ago (259+ words) What Moments in FDA’s Review Process Should Patients and Providers be Watching Closely? Pharmaceutical Executive Nate Hill, Co-Founder & CEO of Strive Pharmacy, outlines the key milestones in the FDA's review process that both patients and providers should be tracking as…...
Managing the Uncertainty of Inventory, Staffing, and Formulary Planning Around Peptides?
1+ week, 4+ day ago (275+ words) Pharmaceutical Executive Nate Hill, Co-Founder & CEO of Strive Pharmacy, describes how the company approaches uncertainty around peptide inventory, staffing, and formulary planning by drawing on its prior experience navigating similarly unsettled situations Hill explains that Strive relies heavily on legal…...
Why Patients Will Use Peptides Regardless of FDA Status | PharmExec
1+ week, 5+ day ago (51+ words) Why Patients Will Use Peptides Regardless of FDA Status Pharmaceutical Executive Beyond Traditional Strategy Consulting Firms: Why MBA Students Should Consider Turnaround, Restructuring Consulting The Industry’s Shift on RWD Why AI Trust Comes Down to One Equation: Q&A with…...
BioNTech Terminates Phase II Clinical Trial for Cevumeran
1+ week, 6+ day ago (512+ words) Pharmaceutical Executive BioNTech has decided to terminate itâs Phase II clinical trial evaluating autogene Cevumeran, an investigational individualized mRNA cancer immunotherapy, as an adjuvant monotherapy in patients with circulating tumor DNA-positive, surgically resected Stage II (high risk) or Stage…...
How Can Restricting Compounded Peptides Affect Current Gray Market Users?
1+ week, 6+ day ago (295+ words) Pharmaceutical Executive Nate Hill, co-founder & CEO of Strive Pharmacy, addresses concerns about where patients would turn if the FDA moves to restrict compounded peptides sourced through gray-market channels Hill points out that many of these research-grade peptide sellers include disclaimers…...
FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer
2+ week, 4+ day ago (411+ words) The FDA has approved Revolution Medicines' daraxonrasib, the first RAS-directed therapy for previously treated metastatic pancreatic adenocarcinoma, based on a phase 3 trial showing a survival benefit over chemotherapy. The FDA has approved daraxonrasib (brand name Rasonque) for adults with metastatic…...
FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia in Patients Aged 12 and Older
2+ week, 5+ day ago (219+ words) FDA approved Imaavy (nipocalimab-aahu) as the first-ever treatment specifically indicated for warm autoimmune hemolytic anemia in patients ages 12 and up. FDA approved Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia in adults and pediatric patients 12 years of age…...
Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech
2+ week, 6+ day ago (84+ words) Hanmi Licenses HM17321 to Genentech | PharmExec Pharmaceutical Executive Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most nominated peptides for the compounding bulks list, and Ivo Carre examines how tau- and microglia-targeted…...
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
2+ week, 6+ day ago (244+ words) Hanmi Pharm has licensed HM17321 to Genentech for up to $2.3 billion, including a $190 million upfront payment. Hanmi Pharm entered into an exclusive licensing agreement with Genentech, a member of the Roche Group, for the worldwide development, manufacturing, and commercialization of HM17321. The…...